FMP
Nymox Pharmaceutical Corporation
NYMX
NASDAQ
Inactive Equity
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.
0.2 USD
-0.0001 (-0.05003%)
Latest NYMX News
InvestorPlace
Jul 6, 2023
Why Is Nymox Pharmaceutical (NYMX) Stock Down 18% Today?
Nymox Pharmaceutical (NASDAQ: NYMX ) stock is falling on Thursday after the company told investors its shares will be delisted. Shares of NYMX stock will no longer trade on the Nasdaq Exchange when markets open on Friday.
Benzinga
May 23, 2022
Why Nymox Pharma Shares Sinking to 52-Week Low?
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) has received a Refusal to File (RTF) letter from FDA regarding its marketing application for Fexapotide Triflutate. Nymox's position is that clarifications remain to be resolved at a follow-up meeting and that some significant.
GlobeNewsWire
Oct 11, 2021
NYMOX Provides Current Update
HASBROUCK HEIGHTS, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to report today a one-month update to shareholders as a follow-up to the September communication. The Company reinforces that its completion tasks for the important Fexapotide filing have advanced as anticipated and that substantial progress has ensued.
GlobeNewsWire
Sep 10, 2021
NYMOX Provides Shareholder Update
HASBROUCK HEIGHTS, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide an update on the Company's progress with its BPH treatment product Fexapotide Triflutate.
PennyStocks
Sep 8, 2021
4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%
These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GlobeNewsWire
Mar 29, 2021
Nymox Provides New Update on Regulatory Activities
HASBROUCK HEIGHTS, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide the latest update on the Company's regulatory filing preparation activities. The Company expects to file for approval for its first in class BPH treatment Fexapotide Triflutate, during the summer of this year. Management will provide a firm exact date for the filing in a subsequent disclosure. This communication of the exact date for the filing will be announced by th...
GlobeNewsWire
Nov 16, 2020
Nymox Provides Update on Regulatory Filing Activities
HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications.
Yahoo
Aug 12, 2020
Nymox Announces $9 Million Registered Direct Offering
HASBROUCK HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of shares of its common stock at a purchase price of $2.50 per share in a registered direct offering for gross proceeds of approximately $9 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about Augu...
Yahoo
Jul 28, 2020
NYMOX Provides Current Update on Key Company Developments
HASBROUCK HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report current updates on the Company's most important ongoing developments. The Company reports further significant and important progress has been made with remaining items for the upcoming regulatory filings in 2020 for the Company's first in class innovative prostate drug Fexapotide Triflutate (FT). The Company has moved swiftly ahead on its regulatory marketing applicatio...
Yahoo
Jun 19, 2020
Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement
Nymox Pharmaceutical Corporation (NYMX) is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of its regulatory documentation has proceeded very well, despite the inherent limitations of the business environment in 2020.
